검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Cemiplimab + Fianlimab [Fixed Dose Combination (FDC, Cemiplimab + Fianlimab [Fixed Dose Combination, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]) Regeneron / Sanofi·Ovarian Cancer ORR 100% |
|---|---|
Overview Program | Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] |
Overview Company | Regeneron / Sanofi |
Overview Modality | ANTIBODY |
Overview Target | Ovarian Cancer |
Overview Indication | Ovarian Cancer; Fallopian Tube Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targets distinct nociceptive pathway |
MoA Biomarker | biomarker in typhoon survivors, reducing the subjective bias associated with clinical symptom scales |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Comparison of pharmacokinetics and safety of fixed-dose versus loose combination of atorvastatin/fenofibrate 10/145 mg in healthy Korean participants.. Dyslipidemia is a risk factor for cardiovascular disease. Atorvastatin and fenofibrate are co-administered to treat mixed dyslipidemia, a subtype requiring long-term control of low-density lipoprotein cholesterol and triglycerides; fixed-dose combi… |
Clinical Primary efficacy | ORR 100% |
Clinical ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT04586244 |
Clinical Data Tier / Score | A · 62 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Cemiplimab + Fianlimab [Fixed Dose Combination (FDC, Cemiplimab + Fianlimab [Fixed Dose Combination, Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)]) Regeneron / Sanofi·Ovarian Cancer ORR 100% |
|---|---|
Overview Program | Cemiplimab + Fianlimab [Fixed Dose Combination (FDC)] |
Overview Company | Regeneron / Sanofi |
Overview Modality | ANTIBODY |
Overview Target | Ovarian Cancer |
Overview Indication | Ovarian Cancer; Fallopian Tube Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targets distinct nociceptive pathway |
MoA Biomarker | biomarker in typhoon survivors, reducing the subjective bias associated with clinical symptom scales |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Comparison of pharmacokinetics and safety of fixed-dose versus loose combination of atorvastatin/fenofibrate 10/145 mg in healthy Korean participants.. Dyslipidemia is a risk factor for cardiovascular disease. Atorvastatin and fenofibrate are co-administered to treat mixed dyslipidemia, a subtype requiring long-term control of low-density lipoprotein cholesterol and triglycerides; fixed-dose combi… |
Clinical Primary efficacy | ORR 100% |
Clinical ORR | 100% |
Clinical Result source | ClinicalTrials.gov NCT04586244 |
Clinical Data Tier / Score | A · 62 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교